Randomized Phase II Trial of Erlotinib in Combination with High Dose-Celecoxib or Placebo in Patients with Advanced Non-small Cell Lung Cancer

BACKGROUND: Cyclooxygenase-2 (COX-2)-dependent signaling represents a potential mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. This is mediated in part through an EGFR-independent activation of MAPK/Erk by PGE2. PGE2 promotes downregulatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Reckamp, Karen L., Koczywas, Marianna, Cristea, Mihaela C., Dowell, Jonathan E., Wang, He-Jing, Gardner, Brian, Milne, Ginger L., Figlin, Robert A., Fishbein, Michael C., Elashoff, Robert M., Dubinett, Steven M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4864011/
https://ncbi.nlm.nih.gov/pubmed/26033830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29480
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados